

Jialiang Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5568626/publications.pdf>

Version: 2024-02-01

17
papers

993
citations

840119

11
h-index

794141

19
g-index

19
all docs

19
docs citations

19
times ranked

1757
citing authors

#	ARTICLE	IF	CITATIONS
1	The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test. <i>European Journal of Pharmacology</i> , 2020, 870, 172909.	1.7	23
2	Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. <i>Journal of the American Chemical Society</i> , 2020, 142, 18874-18885.	6.6	16
3	Tumor-Derived EV-Encapsulated miR-181b-5p Induces Angiogenesis to Foster Tumorigenesis and Metastasis of ESCC. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 421-437.	2.3	37
4	The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2683.	1.8	6
5	Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease. <i>Nature Communications</i> , 2017, 8, 15384.	5.8	40
6	The cytotoxic and tyrosine kinase inhibitory properties of C21 steroids and iridoids from the tubers of <i>Alocasia cucullata</i> . <i>Journal of Natural Medicines</i> , 2016, 70, 602-609.	1.1	4
7	Anti-tumor peptide AP25 decreases cyclin D1 expression and inhibits MGC-803 proliferation via phospho-extracellular signal-regulated kinase-, Src-, c-Jun N-terminal kinase-and phosphoinositide 3-kinase-associated pathways. <i>Molecular Medicine Reports</i> , 2015, 12, 4396-4402.	1.1	9
8	Fusion Peptides CPU1 and CPU2 Inhibit Matrix Metalloproteinases and Protect Mice from Endotoxin Shock Within a Strict Time Window. <i>Inflammation</i> , 2015, 38, 2092-2104.	1.7	2
9	Inhibition of Neutrophil Collagenase/MMP-8 and Gelatinase B/MMP-9 and Protection against Endotoxin Shock. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	6
10	Generation of antitumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment. <i>Anti-Cancer Drugs</i> , 2013, 24, 677-689.	0.7	14
11	Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2012, 15, 555-570.	0.6	18
12	Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF- α converting enzyme (TACE/ADAM-17). <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2012, 27, 533-540.	2.5	8
13	Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 480-498.	21.5	680
14	Inhibition of Lethal Endotoxin Shock with an L-Pyridylalanine Containing Metalloproteinase Inhibitor Selected by High-Throughput Screening of a New Peptide Library. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2006, 9, 599-611.	0.6	14
15	Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. <i>Biochemical Pharmacology</i> , 2005, 70, 535-544.	2.0	49
16	Simulation of Evolution-Selected Propeptide by High-Throughput Selection of a Peptidomimetic Inhibitor on a Capillary DNA Sequencer Platform. <i>Analytical Chemistry</i> , 2005, 77, 2116-2124.	3.2	21
17	Inhibitors of gelatinase B/matrix metalloproteinase-9 activity. <i>Biochemical Pharmacology</i> , 2004, 67, 1001-1009.	2.0	38